Immunoconjugates are specific, effective, minimally toxic anticancer therapies. They allow the delivery of a range of different effectors, including pharmacologic agents, radioisotopes, and toxins, to cancer cells. Of note, highly cytotoxic anticancer molecules could be linked to specific antibodies, which mask the toxic effects of the drug until it reaches its target. This Review summarizes the successes and shortcomings of immunoconjugates, and discusses the future potential for these therapies.
- Brandon G. Smaglo
- Dalal Aldeghaither
- Louis M. Weiner